AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06321861 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Participants will take one caffeine pill. The dose of caffeine will be calculated based on participants' body mass (3mg/kg body mass). Caffeine will be provided in capsules containing the individual amount of caffeine and will be administered orally 60 min before the onset of the exercise protocol.
Study NCT06321861 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take one pill with no caffeine in it. The manufacturer of the caffeine capsules will also prepare identical placebo capsules filled out with a microcrystalline cellulose. Placebo will be administered orally 60 min before the onset of the exercise protocol.
Study NCT06321861 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No substance
Description: Participants will take no substance. They will just wait 60 minutes and then engage in the exercise protocol.
Study NCT05449496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Education Curriculum
Description: Curriculum of dietary education and group-based counseling to encourage whole-food plant-based eating
Study NCT04560764 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Landscape video
Description: Before the execution of the exercises described in the intervention Virtual Reality, the participants in the sham comparator group will see a video of a natural landscape for two minutes.
Study NCT04560764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Participants in both groups will receive the standard treatment, one hour a day for three days a week.
Study NCT04560764 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard treatment
Description: Participants in both groups will receive the standard treatment, one hour a day for three days a week.
Study NCT06460714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shock wave therapy, stretching and orthosis
Description: Shortwave therapy, stretching and orthotics will be provided to Group A. Shock wave session will be provided for 20 minutes thrice a week. Five days in a week provided five minutes with 30 seconds sustained stretch will be provided and than orthotics will be used to obtained the sustained effect.
Study NCT06460714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching, strengthening and orthosis
Description: In Group B spastic diplegic children just given stretching with strengthening and orthotics. We provide sustained 30 seconds stretch with 30 seconds rest for 5 minutes and followed with forty repetition of hip flexor and knee flexors and range will be maintained by applying orthosis.
Study NCT04956666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyophilized S95014
Description: Each patient was administrated, over 1 to 2 hours, every 2 weeks Lyophilized S95014 intravenously at the dose of 1000, 2000 or 2500U/m2, as per investigator's judgement.~In total, 9 infusions of lyophilized S95014 were administrated (at week 7, 9, 11, 15, 17, 19, 23, 25 and 27).Patients received other backbone chemotherapy agents as per ALL-MB 2015.
Study NCT05492526 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ki Monitor without feedback
Description: Physical activity Monitor - No feedback
Study NCT04890886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thermal imaging
Description: Use of a thermal imaging cameral to measure brown and white adipose tissue function
Study NCT05492526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ki monitor with contextualised data feedback
Description: Physical activity monitor and feedback
Study NCT04890886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Echocardiographic imaging of the fetal heart to assess ventricular function
Study NCT06303076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tizanidine Hcl 4Mg Tab
Description: Initial Dose Administration:~Patients will start by taking an initial dose of 2 mg of Tizanidine at bedtime (HS).~Dose Titration Process:~Every 4 days, the dose of Tizanidine will be increased by 2 mg. This titration is based on the patient's response to the medication and their tolerability of it.~Maximum Dose Limit:~The dose titration will continue until reaching the maximum dose of 0.1 mg/kg/HS, or until the maximum tolerated dose is identified, whichever comes first.~Monitoring and Adjustment:~Throughout the titration process, patients will be closely monitored for any adverse effects and for the effectiveness of the medication.~Adjustments to the dosing schedule may be made based on the clinician's assessment of tolerability and therapeutic response.
Study NCT06303076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem Tartrate 10 mg
Description: nitial Dose Administration:~Participants will start by taking an initial dose of Zolpidem 5 mg orally at home before bedtime (HS).~Response Evaluation and Dose Adjustment:~If there is no response to the initial 5 mg dose and it is tolerated well by the participant, the dose will be increased to 10 mg.~Monitoring and Adjustment:~Participants will be monitored for their response to the medication as well as for any adverse effects.~The decision to increase the dose to 10 mg will be based on the absence of a therapeutic response to the initial dose and the participant's tolerability of Zolpidem.~Dose Maximization and Safety:~The increase to a 10 mg dose is aimed at maximizing therapeutic efficacy while ensuring the safety and tolerability of the medication in participants who do not respond to the lower dose.
Study NCT05817266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Field-cycling imaging (FCI)
Description: FCI scan
Study NCT05276232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis(THC) inhaled
Description: Cannabis vapor is produced from 500mg, approximately 5-10% High dose bulk cannabis plant material, 30-37.5 mg THC
Study NCT05671640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DragonFly-T Transcatheter Tricuspid Valve Repair System
Description: To conduct edge-to-edge repair with DragonFly-T System under the guidance of transesophageal echocardiography.
Study NCT06259643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power wheelchair soccer
Description: Participants will practice power wheelchair soccer during the course of the power wheelchair soccer season (starting in November 2023 and ending in June 2024). Sessions are given once a week, by a coach with experience in this adaptive sport.
Study NCT04754412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral, Psychological or Informational Intervention
Description: Write about stress and coping, emotional disclosure, and benefit finding
Study NCT04754412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral, Psychological or Informational Intervention
Description: Write about positive thoughts and feelings regarding their breast cancer experience
Study NCT04754412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Write about facts regarding their cancer diagnosis and treatment
Study NCT04754412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04754412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04754412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04754412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05792332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Patients are followed up by a nurse specialist in parkinsonism who interacts with the treating neurologist and a multidisciplinary team
Study NCT05792332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care
Description: Patients are managed only by the neurologist according the institution's clinical practice
Study NCT06005285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM)
Description: The Early Start Denver Model focuses on teaching inside children's play and care activities, carried out within a joint activity structure. Adults follow children's leads into activities, embed teaching objectives inside the play, use the play as the reward, and build targeted skills following developmental science and ABA principles.
Study NCT06005285 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Intensive Behavioral Intervention (EIBI)
Description: Treatment as usual provided by community-based autism agencies
Study NCT05459402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone (100% dose)
Description: Methadone for the treatment of opioid use disorder
Study NCT05341986 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Decision Support (CDS) tool
Description: Implementation of an EHR-based CDS tool for providers to use.
Study NCT05549765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacopuncture
Description: Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.
Study NCT05549765 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Korean medical treatment
Description: acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
Study NCT05549765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Korean medical treatment
Description: acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
Study NCT05149092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chicken protein hydrolysate supplement
Description: Daily oral self-administration of 18 g of supplement dissolved in water/mineral water, spread over 2-3 occasions
Study NCT05149092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral self-administration of 18 g of supplement dissolved in water/mineral water, spread over 2-3 occasions
Study NCT05459402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone (50% dose)
Description: Methadone for the treatment of opioid use disorder
Study NCT05866744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet
Description: 18 patients with NAFLD will be asked to follow an early 14:10 (14 hours fasting and 10 hours feeding) time-restricted (eating between 08:00-18:00) and individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) for 12 weeks
Study NCT05866744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet
Description: 18 patients with NAFLD will be asked to follow a late 14:10 (14 hours fasting and 10 hours feeding) time-restricted (eating between 12:00-22:00) and individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) for 12 weeks
Study NCT04890886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: ECG of the fetus and the neonate to look at the cardiac electrical activity
Study NCT05371522 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]DPA-714 positron emission tomography (PET) scan
Description: 60 minute dynamic brain \[18F\]DPA-714 positron emission tomography (PET) scan followed by a 30 minute static whole body positron emission tomography (PET) scan
Study NCT05188521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib (LY3009104) 2 mg
Description: 2 mg orally administered once daily for 16 weeks
Study NCT05188521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib (LY3009104) 4 mg
Description: 4 mg orally administered once daily for 12 weeks
Study NCT05263219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dTACE-HAIC
Description: For DEB-TACE, superselective catheterization is performed and CalliSpheres loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In patients with huge or bilobar multiple lesions, in order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session.~After each chemoembolization, the microcatheter is reserved at the proper/left/right hepatic artery. The FOLFOX-based regimen is intra-arterially administered.~During follow-up, the treatment will be repeated on demand (at a 4-6-week interval usually) based on the evaluation of the follow-up laboratory and imaging examination.
Study NCT05263219 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HAIC
Description: HAIC treatment is divided into 3-week cycles. The microcatheter is advanced into the proper/left/right hepatic artery on day 1 in every cycle of treatment. After the patient returned to the ward, the FOLFOX-based regimen is intra-arterially administered though the microcatheter.~The treatment is repeated once every 3 weeks for up to six cycles.
Study NCT05263219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dTACE-HAIC protocol
Description: CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.~FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
Study NCT05263219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAIC protocol
Description: FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
Study NCT04884581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GI Genius CADx device
Description: GI Genius System is an Intelligent Endoscopy Module designed to be an adjunct to video colonoscopy with the purpose of supporting the operating physician with artificial intelligence during colonoscopy. GI Genius CADx is the AI software that provides a histology prediction of framed polyps during real-time colonoscopy, with each polyp being classified as adenoma or non-adenoma.
Study NCT05485675 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stand & Move at Work
Description: Web-based platform only.
Study NCT05485675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stand & Move at Work+
Description: Web-based platform and support from an expert facilitator
Study NCT06138535 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: digital stabilizing splint
Description: 3D Printed stabilizing splint that has been digitally designed on a modern software
Study NCT05866744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric Mediterranean Diet Without Time Restriction In Feeding
Description: 18 patients with NAFLD will be asked to follow an individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) without time restriction in feeding (eating throughout the day) for 12 weeks
Study NCT03978325 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive standard pre-operative care. This involves standard pre-operative advice and a moderate intensity preoperative exercise programme.
Study NCT03978325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise - HIIT Intervention
Description: The HIIT intervention will take the form of a supervised programme, completed for at least two weeks, up to 5 days per week preoperatively. The HIIT intervention will be performed on a cycle ergometer. Exercise sessions will be individually supervised and scheduled at a time of convenience for each participant. Each exercise session will last 40 minutes and will include warm-up, exercise training and cool-down components. Lactate threshold, measured during the baseline CPT, will be used to determine the exercise intensity.~The training protocol will prescribe 15 second intervals of exercise and passive recovery. The highest resistance reached during the baseline CPET (measured in watts) will be recorded as the peak power output (PPO). During training, participants will undergo a 5-minute warm-up at 50% PPO, followed by up to 30 minutes of HIIT with intervals of 15 seconds at 100% PPO with 15 second recovery periods at 0 watts.
Study NCT05787561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib (VS-6766)
Description: 3.2 mg PO, twice weekly
Study NCT05787561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: 200 mg PO BID for 3 weeks, followed by a 1 week rest period, in each 4-week (28 day) cycle.
Study NCT06411535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full-mouth ultrasonic debridement plus Nutritional counseling
Description: After diagnosis of gingivitis, patients will receive a nutritional counseling focused on ultra-processed foods entails educating individuals about the nutritional content and potential health implications of highly processed food products. They will undergo a session of full-mouth ultrasonic debridement and reinforcment of dietary counseling. Between consecutive time points, patients will receive motivational emails.
Study NCT06411535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth ultrasonic debridement
Description: After diagnosis of gingivitis, patients will receive a session of full mouth ultrasonic debridement
Study NCT06177535 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kavalactones
Description: Three 75 mg capsules orally once daily within one hour of bedtime (225 mg total/day)
Study NCT06177535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three capsules orally once daily within one hour of bedtime. Looks exactly like the study drug, but it contains no active ingredient.
Study NCT04890886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: MRI scan of the neonate to assess adipose tissue, liver architecture and cardiac structure and function
Study NCT04890886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum blood markers
Description: Serum sample taken from mother before birth and umbilical cord or neonatal blood spot at birth to assess glucose levels / lipid levels and lipidomics and cardiac function (using NTproBNP) as a marker
Study NCT05981664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One Handed Video Game Controller Adapter
Description: The one handed video game controller adapter was designed and 3D printed at Rehabilitation Centre for Children. It is a simple model that snaps onto an XBox One controller and uses a series of levers to allow access to almost all buttons of the controller from one side. There is both left and right sided versions
Study NCT05892666 — intervention group
Intervention type: OTHER
Intervention: On-site recruitment (information and consent) following a random sampling recruitment schedule
Description: A trained research assistant in collaboration with local clerks at each site will screen eligible patients after on-site registration or online scheduling, but prior to assessment by a physician, based on included presenting complaints. The research assistant or member of the care team, depending on the local rules, will approach the potentially eligible participants and present them the research project and information consent form. If the patient agrees to participate and is eligible, they will sign the information and consent form and the research assistant will take their vital signs (for onsite participants only).
Study NCT05892666 — intervention group
Intervention type: OTHER
Intervention: First phone call 1-3 days after the initial visit
Description: Once the patient has been discharged, a research assistant will call the patient within 72 hours following the initial visit. This phone call will allow to i) ensure that gender, ethnicity, comorbidities and disposition plans are fully documented; and ii) use our patient-reported experience measure tool and administer a questionnaire on motivation for choosing one care setting over the other. Motivation will be classified in the 6 domains of the Conceptual Model of Emergency Department Use (Uscher-Pines et al. 2019). Participants will be asked to specify whether their choice of care setting was based on accessibility, convenience, their perception of the severity of illness, their beliefs and knowledge regarding these care settings, referral/advice from a care professional or an acquaintance, or on costs.
Study NCT05892666 — intervention group
Intervention type: OTHER
Intervention: Second phone call 8-14 days after the initial visit
Description: A follow-up phone call will be made to all participants 8 days after the initial visit to evaluate primary and secondary outcome metrics. Patient-reported outcome (primary) and cost measures will be completed by the participants at this moment.
Study NCT05916976 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cardiac MRI
Description: Multiparametric MRI of the heart